Drug intelligence / Profile preview

thymostimulin

Development stage
Unknown
Lead developer
CytoChemia
Modality
Recombinant Proteins and Enzymes
Administration
Subcutaneous
01

Overview

Thymostimulin is a **standardized peptide fraction** derived from bovine thymus glands, prepared by extracting and purifying low-molecular-weight thymic peptides while removing higher-molecular-weight proteins and cell components[1][3]. It contains immunomodulatory peptides such as thymosin-α1 and thymic humoral factor. Its mechanism is believed to involve stimulation of proinflammatory cytokines, enhancement of T-cell proliferation and differentiation, and increased antigen expression on tumor cells, resulting in cytotoxic immune responses, particularly against tumor cells[1][3]. Thymostimulin was primarily investigated for use in advanced **hepatocellular carcinoma** (HCC) and other immunodeficiency or cancer-associated conditions. It was developed as a **licensed immunomodulating agent**, with phase II and phase III clinical trials performed in HCC and advanced AIDS-related complex[1][2][3].

Brand names
Thymophysin CytoChemia 25/50
Other names
thymic peptide fraction

Beyond the preview

Go deeper on thymostimulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on thymostimulin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call